Tuesday, April 26, 2016

BRIEF-Ipsen partner Exelixis obtains FDA approval of CABOMETYX tablets

* Announces that its partner Exelixis obtained FDA

approval of CABOMETYX (cabozantinib) tablets for patients with

advanced renal cell carcinoma who have received prior

anti-angiogenic therapy

Source...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)